Recombinant Human SENP7/SSP2 protein is a Human Fragment protein, in the 695 to 864 aa range, expressed in Escherichia coli, with >95% purity, < 1 EU/µg endotoxin level and suitable for SDS-PAGE, HPLC.
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application SDS-PAGE | Reactivity Reacts | Dilution info - | Notes - |
Application HPLC | Reactivity Reacts | Dilution info - | Notes - |
Protease that acts as a positive regulator of the cGAS-STING pathway by catalyzing desumoylation of CGAS. Desumoylation of CGAS promotes DNA-binding activity of CGAS, subsequent oligomerization and activation (By similarity). Deconjugates SUMO2 and SUMO3 from targeted proteins, but not SUMO1 (PubMed:18799455). Catalyzes the deconjugation of poly-SUMO2 and poly-SUMO3 chains (PubMed:18799455). Has very low efficiency in processing full-length SUMO proteins to their mature forms (PubMed:18799455).
KIAA1707, SSP2, SUSP2, SENP7, Sentrin-specific protease 7, SUMO-1-specific protease 2, Sentrin/SUMO-specific protease SENP7
Recombinant Human SENP7/SSP2 protein is a Human Fragment protein, in the 695 to 864 aa range, expressed in Escherichia coli, with >95% purity, < 1 EU/µg endotoxin level and suitable for SDS-PAGE, HPLC.
pH: 7.4
Constituents: 5% Glycerol (glycerin, glycerine), 0.48% HEPES
The purity of ab151868 is greater than 95%, as determined by SEC-HPLC and reducing SDS-PAGE. It is lyophilized from an 0.2 µM filtered solution.
Protease that acts as a positive regulator of the cGAS-STING pathway by catalyzing desumoylation of CGAS. Desumoylation of CGAS promotes DNA-binding activity of CGAS, subsequent oligomerization and activation (By similarity). Deconjugates SUMO2 and SUMO3 from targeted proteins, but not SUMO1 (PubMed:18799455). Catalyzes the deconjugation of poly-SUMO2 and poly-SUMO3 chains (PubMed:18799455). Has very low efficiency in processing full-length SUMO proteins to their mature forms (PubMed:18799455).
Belongs to the peptidase C48 family.
This product was previously labelled as SENP7
SENP7 also known as SSP2 functions mechanically as a SUMO protease with a mass of approximately 126 kDa. It belongs to the SENP family of proteases responsible for deSUMOylation which involves the removal of SUMO groups from target proteins. SENP7 shows expression in various tissues with particular prevalence in the brain and skeletal muscle. It plays an essential role in post-translational modification by regulating the SUMOylation state influencing protein activity stability and interactions.
DeSUMOylation is critical for regulating protein function and SENP7 plays a significant role in this process. It removes small ubiquitin-related modifier (SUMO) proteins from substrates therefore modulating protein function and interactions. SENP7 is not known to be part of large multiprotein complexes unlike some other members of the SUMO protease family. The precise SUMO motifs and substrates of SENP7 influence cellular functions such as DNA repair signal transduction and transcriptional regulation responding to cellular stress.
SENP7 acts within the SUMOylation pathway a post-translational modification pathway known for regulating a variety of protein functions. It is particularly associated with pathways controlling cellular stress responses and chromatin dynamics similar to other members of the SENP family such as SENP1 and SENP2. This involvement in chromatin remodeling links SENP7 to regulating genes associated with cellular stress resilience. It helps maintain the balance of SUMO-conjugated proteins in response to environmental changes impacting cell cycle regulation and apoptosis.
SENP7 connects with several conditions like cancer and neurological disorders. Aberrant SENP7 activity can lead to dysregulated SUMOylation contributing to the progression of these diseases. In cancer changes in SENP7 function relate to the altered expression of proteins involved in cell proliferation such as p53 a well-known tumor suppressor. In neurological diseases SENP7 might interact with proteins like tau influencing their SUMOylation state and aggregation tendencies which are critical in neurodegenerative disorders like Alzheimer's disease.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Lane 1: Reduced conditions, ab151868 3-5 μg
Lane 2: Non reduced conditons, ab151868 3-5 μg
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com